Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10362239" target="_blank" >RIV/00216208:11110/17:10362239 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10362239 RIV/00159816:_____/17:00068982

Výsledek na webu

<a href="http://dx.doi.org/10.3892/ol.2017.5723" target="_blank" >http://dx.doi.org/10.3892/ol.2017.5723</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/ol.2017.5723" target="_blank" >10.3892/ol.2017.5723</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure

Popis výsledku v původním jazyce

The primary objective of the present prospective study was to compare the diagnostic performance of conventional radiography (CR) and whole-body low-dose computed tomography (WBLDCT) with a comparable radiation dose reconstructed using hybrid iterative reconstruction technique, in terms of the detection of bone lesions, skeletal fractures, vertebral compressions and extraskeletal findings. The secondary objective was to evaluate lesion attenuation in relation to its size. A total of 74 patients underwent same-day skeletal survey by CR and WBLDCT. In CR and WBLDCT, two readers assessed the number of osteolytic lesions at each region and stage according to the International Myeloma Working Group (IMWG) criteria. A single reader additionally assessed extraskeletal findings and their significance, the number of vertebral compressions and bone fractures. The radiation exposure was 2.7 +/- 0.9 mSv for WBLDCT and 2.5 +/- 0.9 mSv for CR (P= 0.054). CR detected bone involvement in 127 out of 486 regions (26%; P&lt; 0.0001), confirmed by WBLDCT. CR underestimated the disease stage in 16% and overestimated it in 8% of the patients (P= 0.0077). WBLDCT detected more rib fractures compared with CR (188 vs. 47; P&lt; 0.0001), vertebral compressions (93 vs. 67; P= 0.010) and extraskeletal findings (194 vs. 52; P&lt; 0.0001). There was no correlation observed between lesion size (&gt;= 5 mm) and its attenuation (r= -0.006; P= 0.93). The inter-observer agreement for the presence of osteolytic lesions was kappa= 0.76 for WBLDCT, and kappa= 0.55 for CR. The present study concluded that WBLDCT with hybrid iterative reconstruction technique demonstrates superiority to CR with an identical radiation dose in the detection of bone lesions, skeletal fractures, vertebral compressions and extraskeletal findings, which results in up-or downstaging in 24% patients according to the IMWG criteria. The attenuation of osteolytic lesions can be measured with the avoidance of the partial volume effect.

Název v anglickém jazyce

Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure

Popis výsledku anglicky

The primary objective of the present prospective study was to compare the diagnostic performance of conventional radiography (CR) and whole-body low-dose computed tomography (WBLDCT) with a comparable radiation dose reconstructed using hybrid iterative reconstruction technique, in terms of the detection of bone lesions, skeletal fractures, vertebral compressions and extraskeletal findings. The secondary objective was to evaluate lesion attenuation in relation to its size. A total of 74 patients underwent same-day skeletal survey by CR and WBLDCT. In CR and WBLDCT, two readers assessed the number of osteolytic lesions at each region and stage according to the International Myeloma Working Group (IMWG) criteria. A single reader additionally assessed extraskeletal findings and their significance, the number of vertebral compressions and bone fractures. The radiation exposure was 2.7 +/- 0.9 mSv for WBLDCT and 2.5 +/- 0.9 mSv for CR (P= 0.054). CR detected bone involvement in 127 out of 486 regions (26%; P&lt; 0.0001), confirmed by WBLDCT. CR underestimated the disease stage in 16% and overestimated it in 8% of the patients (P= 0.0077). WBLDCT detected more rib fractures compared with CR (188 vs. 47; P&lt; 0.0001), vertebral compressions (93 vs. 67; P= 0.010) and extraskeletal findings (194 vs. 52; P&lt; 0.0001). There was no correlation observed between lesion size (&gt;= 5 mm) and its attenuation (r= -0.006; P= 0.93). The inter-observer agreement for the presence of osteolytic lesions was kappa= 0.76 for WBLDCT, and kappa= 0.55 for CR. The present study concluded that WBLDCT with hybrid iterative reconstruction technique demonstrates superiority to CR with an identical radiation dose in the detection of bone lesions, skeletal fractures, vertebral compressions and extraskeletal findings, which results in up-or downstaging in 24% patients according to the IMWG criteria. The attenuation of osteolytic lesions can be measured with the avoidance of the partial volume effect.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncology Letters

ISSN

1792-1074

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

5

Strana od-do

2490-2494

Kód UT WoS článku

000398514200071

EID výsledku v databázi Scopus

2-s2.0-85015316373